Anti-PD-L1 antibodies and antibody-drug conjugates
US12421312B2 · kind B2 · utility
0Cited by
28References
51Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2020 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Oct 31, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.